{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T08:07:27Z","timestamp":1770538047885,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"VA","doi-asserted-by":"publisher","award":["I01BX001957"],"award-info":[{"award-number":["I01BX001957"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"VA","doi-asserted-by":"publisher","award":["I01BX001018"],"award-info":[{"award-number":["I01BX001018"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"VA","doi-asserted-by":"publisher","award":["I01BX000327"],"award-info":[{"award-number":["I01BX000327"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA163499"],"award-info":[{"award-number":["R01CA163499"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.bone.2016.07.007","type":"journal-article","created":{"date-parts":[[2016,7,16]],"date-time":"2016-07-16T10:05:36Z","timestamp":1468663536000},"page":"81-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease"],"prefix":"10.1016","volume":"91","author":[{"given":"Jeffry S.","family":"Nyman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa R.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasidhar","family":"Uppuganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijaya","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander J.","family":"Makowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babatunde O.","family":"Oyajobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie A.","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.bone.2016.07.007_bb0005","doi-asserted-by":"publisher","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.bone.2016.07.007_bb0010","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.bone.2016.07.007_bb0015","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S8756-3282(97)00056-2","article-title":"A murine model of human myeloma bone disease","volume":"20","author":"Garrett","year":"1997","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2016.07.007_bb0020","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1586\/17474086.2013.874943","article-title":"Management of bone disease in multiple myeloma","volume":"7","author":"Terpos","year":"2014","journal-title":"Expert. Rev. Hematol."},{"issue":"2","key":"10.1016\/j.bone.2016.07.007_bb0025","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jbo.2013.04.001","article-title":"Myeloma bone disease: Pathophysiology and management","volume":"2","author":"Silbermann","year":"2013","journal-title":"J. Bone Oncol."},{"issue":"8","key":"10.1016\/j.bone.2016.07.007_bb0030","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bone.2016.07.007_bb0035","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027090","article-title":"Anti-transforming growth factor \u03b2 antibody treatment rescues bone loss and prevents breast cancer metastasis to bone","volume":"6","author":"Biswas","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bone.2016.07.007_bb0040","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1476-4598-10-2","article-title":"Efficient TGF-beta\/SMAD signaling in human melanoma cells associated with high c-SKI\/SnoN expression","volume":"10","author":"Javelaud","year":"2011","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.bone.2016.07.007_bb0045","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/0008-5472.CAN-10-2993","article-title":"TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical hedgehog signaling","volume":"71","author":"Johnson","year":"2011","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bone.2016.07.007_bb0050","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bone.2010.05.036","article-title":"TGF-beta-related mechanisms of bone destruction in multiple myeloma","volume":"48","author":"Matsumoto","year":"2011","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2016.07.007_bb0055","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1158\/0008-5472.CAN-10-2651","article-title":"TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases","volume":"71","author":"Mohammad","year":"2011","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bone.2016.07.007_bb0060","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1172\/JCI3523","article-title":"TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development","volume":"103","author":"Yin","year":"1999","journal-title":"J. Clin. Invest."},{"issue":"52","key":"10.1016\/j.bone.2016.07.007_bb0065","doi-asserted-by":"publisher","first-page":"18813","DOI":"10.1073\/pnas.0507417102","article-title":"TGF-beta regulates the mechanical properties and composition of bone matrix","volume":"102","author":"Balooch","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.bone.2016.07.007_bb0070","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1002\/jbmr.139","article-title":"Inhibition of TGF-beta signaling by 1D11 antibody treatment increases bone mass and quality in vivo","volume":"25","author":"Edwards","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2016.07.007_bb0075","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive transforming growth factor-beta signaling is a common mechanism in osteogenesis imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bone.2016.07.007_bb0080","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/jbmr.2120","article-title":"Role of TGF-beta in a mouse model of high turnover renal osteodystrophy","volume":"29","author":"Liu","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.07.007_bb0085","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.biomaterials.2015.06.026","article-title":"Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin beta3 and TGF-beta receptor type II","volume":"64","author":"Page","year":"2015","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.bone.2016.07.007_bb0090","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/107327480301000502","article-title":"Bortezomib (PS-341): A novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers","volume":"10","author":"Richardson","year":"2003","journal-title":"Cancer Control"},{"issue":"1","key":"10.1016\/j.bone.2016.07.007_bb0095","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ajh.21310","article-title":"The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo","volume":"84","author":"Pennisi","year":"2009","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.bone.2016.07.007_bb0100","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.2174\/138920111798808392","article-title":"Antibody targeting of TGF-beta in cancer patients","volume":"12","author":"Lonning","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"2","key":"10.1016\/j.bone.2016.07.007_bb0105","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1081\/IPH-120020473","article-title":"Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice","volume":"25","author":"Ruzek","year":"2003","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"10","key":"10.1016\/j.bone.2016.07.007_bb0110","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1158\/0008-5472.CAN-08-0215","article-title":"An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments","volume":"68","author":"Nam","year":"2008","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bone.2016.07.007_bb0115","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26218","article-title":"Immunological effects of the TGFbeta-blocking antibody GC1008 in malignant pleural mesothelioma patients","volume":"2","author":"Stevenson","year":"2013","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.bone.2016.07.007_bb0120","first-page":"392","article-title":"Cellular immunotherapy in multiple myeloma: lessons from preclinical models","volume":"1846","author":"Binsfeld","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.bone.2016.07.007_bb0125","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1158\/1535-7163.MCT-07-0121","article-title":"Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging","volume":"6","author":"Oyajobi","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bone.2016.07.007_bb0130","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bone.2016.07.007_bb0135","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"Bouxsein","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2016.07.007_bb0140","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.bone.2007.07.007","article-title":"Automatic segmentation of cortical and trabecular compartments based on a dual threshold technique for in vivo micro-CT bone analysis","volume":"41","author":"Buie","year":"2007","journal-title":"Bone"},{"issue":"22","key":"10.1016\/j.bone.2016.07.007_bb0145","doi-asserted-by":"publisher","first-page":"5872","DOI":"10.1182\/blood-2011-01-330407","article-title":"Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease","volume":"118","author":"Fowler","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bone.2016.07.007_bb0150","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jbiomech.2009.01.016","article-title":"Quantitative measures of femoral fracture repair in rats derived by micro-computed tomography","volume":"42","author":"Nyman","year":"2009","journal-title":"J. Biomech."},{"issue":"1","key":"10.1016\/j.bone.2016.07.007_bb0155","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.bone.2013.08.002","article-title":"Acute exposure to high dose gamma-radiation results in transient activation of bone lining cells","volume":"57","author":"Turner","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.07.007_bb0160","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/bonekey.2015.31","article-title":"Predicting mouse vertebra strength with micro-computed tomography-derived finite element analysis","volume":"4","author":"Nyman","year":"2015","journal-title":"Bonekey Rep"},{"issue":"4","key":"10.1016\/j.bone.2016.07.007_bb0165","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.bone.2009.12.009","article-title":"Contribution of the intra-specimen variations in tissue mineralization to PTH- and raloxifene-induced changes in stiffness of rat vertebrae","volume":"46","author":"Easley","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.07.007_bb0170","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.bone.2016.07.007_bb0175","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.4161\/cc.8.20.9727","article-title":"Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis","volume":"8","author":"Bierie","year":"2009","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.bone.2016.07.007_bb0180","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1089\/oli.2006.0053","article-title":"Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I\/II studies","volume":"17","author":"Hau","year":"2007","journal-title":"Oligonucleotides"},{"issue":"3","key":"10.1016\/j.bone.2016.07.007_bb0185","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090353","article-title":"Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma","volume":"9","author":"Morris","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.bone.2016.07.007_bb0190","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ki.2011.33","article-title":"A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis","volume":"79","author":"Trachtman","year":"2011","journal-title":"Kidney Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216301879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216301879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T03:33:23Z","timestamp":1568172803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328216301879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":38,"alternative-id":["S8756328216301879"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2016.07.007","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2016.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}